N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: A meta-analysis of epidemiological studies

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 31-37

  Wu, Ke ^a   Wang, Xianding ^a   Xie, Zhiyuan ^a   Liu, Zhihong ^a   Lu, Yiping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bladder cancer; Genetic polymorphism; Meta analysis; N acetyltransferase (NAT1)

Indexed keywords

ALLELE; ARTICLE; ASIAN; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; META ANALYSIS (TOPIC); NAT I GENE; RACE DIFFERENCE; SMOKING; STUDY DESIGN; TUMOR GENE;

EID: 84878385173     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513476988     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay J, Parkin DM and Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Zhu X, Zhong Z, Zhang X, et al. DNA repair gene XRCC3 T241M polymorphism and bladder cancer risk in a Chinese population. Genet Test Mol Biomarkers 2012; 16: 640-643.
4. Yuan Q, Wang M, Wang M, et al. Macrophage migration inhibitory factor gene-173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis. Mol Biol Rep 2012; 39: 3109-3115.
5. Sun XF, Sun ZY, Pan B, et al. Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer. Mol Biol Rep 2012; 39: 5631-5636.
6. Mittal RD, Gangwar R, Mandal RK, et al. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. Mol Biol Rep 2012; 39: 1667-1675.
7. Jaiswal PK, Goel A, Mandhani A, et al. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 2012; 39: 5615-5621.
8. Guney AI, Ergec DS, Tavukcu HH, et al. Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. Genet Test Mol Biomarkers 2012; 16: 672-678.
9. Chu H, Ma L, Wang M, et al. The polymorphisms of IL-4, IL-4R and IL-13 genes and bladder cancer risk in a Chinese population: a case-control study. Mol Biol Rep 2012; 39: 5349-5357.
10. Hsieh FI, Pu YS, Chern HD, et al. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 1999; 81: 537-541.
11. Vatsis KP and Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301: 71-76.
12. Cai J, Zhao Y, Zhu CL, et al. The association of NAT1 polymorphisms and colorectal carcinoma risk: evidence from 20,000 subjects. Mol Biol Rep 2012; 39: 7497-7503.
13. Bell DA, Badawi AF, Lang NP, et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55: 5226-5229.
14. Jaskula-Sztul R, Sokolowski W, Gajecka M, et al. Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. J Appl Genet 2001; 42: 223-231.
15. Ratliff TL. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. J Urol 2005; 174: 2066.
16. Okkels H, Sigsgaard T, Wolf H, et al. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6: 225-231.
17. Stern MC, Johnson LR, Bell DA, et al. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1004-1011.
18. Gu J, Liang D, Wang Y, et al. Effects of Nacetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 2005; 581: 97-104.
19. García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-659.
20. McGrath M, Michaud D and De Vivo I. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC Cancer 2006; 6: 239.
21. Covolo L, Placidi D, Gelatti U, et al. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 2008; 23: 355-362.
22. Cascorbi I, Roots I and Brockmöller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001; 61: 5051-5056.
23. Hung RJ, Boffetta P, Brennan P, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a highrisk population. Int J Cancer 2004; 110: 598-604.
24. Taylor JA, Umbach DM, Stephens E, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure threeway interaction. Cancer Res 1998; 58: 3603-3610.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
26. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
27. Zeegers MP, Tan FE, Dorant E, et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a metaanalysis of epidemiologic studies. Cancer 2000; 89: 630-639.
28. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 2009; 125: 131-151.